KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Net Income: 2011-2024

Historic Net Income for Esperion Therapeutics (ESPR) over the last 14 years, with Dec 2024 value amounting to -$4.8 million.

  • Esperion Therapeutics' Net Income fell 2.90% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.8 million, marking a year-over-year decrease of 160.12%. This contributed to the annual value of -$4.8 million for FY2024, which is 97.74% up from last year.
  • Per Esperion Therapeutics' latest filing, its Net Income stood at -$4.8 million for FY2024, which was up 97.74% from -$214.5 million recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Net Income registered a high of -$4.8 million during FY2024, and its lowest value of -$273.1 million during FY2021.
  • In the last 3 years, Esperion Therapeutics' Net Income had a median value of -$214.5 million in 2023 and averaged -$151.9 million.
  • In the last 5 years, Esperion Therapeutics' Net Income slumped by 89.55% in 2021 and then skyrocketed by 97.74% in 2024.
  • Esperion Therapeutics' Net Income (Yearly) stood at -$144.1 million in 2020, then slumped by 89.55% to -$273.1 million in 2021, then increased by 13.47% to -$236.3 million in 2022, then climbed by 9.21% to -$214.5 million in 2023, then skyrocketed by 97.74% to -$4.8 million in 2024.